All News
Does Methotrexate Work in Giant Cell Arteritis?
There seems to be both hope and uncertainty regarding the use of weekly methotrexate (MTX) in giant cell arteritis (GCA) patients whom need to limit their glucocorticoid use.
Read Article
IL-6 Blocker Succeeds in Real-World Vasculitis
Tocilizumab (Actemra) was effective for refractory giant cell arteritis (GCA) in real-world practice, although serious infections occurred relatively frequently, Spanish investigators reported.
Read Article
RheumNow Podcast – A Grand New Year (1.4.19)
Dr. Jack Cush reviews the news and journals for the beginning of 2019. All from RheumNow.com.
Best wishes for a charmed 2019! My advice: 1. Just show up. 2. If you can, then you must do. 3. Live each day as if it twas your 1st day/last day/make or break day. 4. Teach.
RheumNow Podcast – To Needle or Not to Needle (11.30.18)
Dr. Jack Cush updates the news and reports from the past week at RheumNow.com:
Read Article
FDA Approves Biosimilar Rituximab for NHL, not RA
The U.S. Food and Drug Administration on Wednesday approved Celltrion biosimilar of rituximab called Truxima; previously called CT-P10, now generically labeled as rituximab-abbs. This is the first biosimilar to the Rituxan currently approved to treat non-Hodgkin’s lymphoma. Truxima is not approved for use in rheumatoid arthritis, vasculitis, pemphigus vulgaris or chronic lymphocytic leukemia.
Read Article
The RheumNow Podcast – Heartbreak of Methotrexate (11.16.18)
Dr. Jack Cush reviews the news from the past week at RheumNow.com.
Read Article
Pilot Data on Rituximab in Henoch-Schonlein Purpura
Management of Henoch-Schonlein purpura (HSP) can be challenging as supportive care and avoidance of corticosteroids are often insufficient options. A new series of case reports and literature review of steroid refractory HSP suggests that rituximab may be effective in reducing hospital admissions, overall steroid use, and is capable of inducing remission.
Read Article
IgG4-Related Disease: First Draft Criteria Presented at ACR 2018
As Dr. John Stone, MD, MPH recounted in his presentation regarding the new ACR/EULAR Classification Criteria for IgG4-Related Disease (IgG4-RD), only 15 years prior, IgG4-related disease was an unknown entity in the medical community.
Read Article
RheumNow ACR Week in Review: ACR Wrap-Up (10.26.18)
This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups. ACR 2018 highlights for me included:
Read Article
Early Promise for Steroid-free Approach for Giant Cell Arteritis
A very small study presented at ACR18 looking at tocilizumab monotherapy in patients with a new diagnosis of giant cell arteritis has nevertheless given hope to the tantalising idea that some GCA patients might achieve drug-free remission without steroids, although broader data are requ
Read Article
ACR 2018 - Day 3 Report
Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included:
The PEXIVAS Study – 2x2 Trial of Plasma Exchange and Reduced Steroids in ANCA-Associated Vasculitis (AAV) - Abstract #2788
Read Article
Excess Mortality in CTD or Systemic Vasculitis Patients
The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.
Read Article
An Association between GCA and IBD ?
A population based analysis from Israel suggests that giant cell arteritis (GCA) patients may be at increased risk for inflammatory bowel diseases (IBD) mainly target.
Read Article
IL-12 and IL-23 Promote Giant Cell Arteritis
It has been postulated that TH1 and TH17 pathways are implicated in the pathogenesis of giant cell arteritis (GCA); this is supported by new research showing that interleukin 12 (IL-12) and interleukin 23 (IL-23) may stimulate inflammatory and proliferative pathways relevant to the path
Read Article
The RheumNow Week in Review – No Good Gout (8.10.18)
Dr. Jack Cush reviews the news and latest journal articles from the past week on RheumNow.com. Info on Surgery and Hip Fractures, Gout drugs abandoned, Allopurinol escalation, hydroxychloroquine drug levels, how to treat scleroderma in India and exactly who gets back pain.
Read Article
The RheumNow Week in Review – Lupus in the News (7.27.18)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
The RheumNow Week in Review –Fateful Outcomes in Rheumatology (7.13.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Fateful outcomes in Rheumatology, what happens to Seronegatives, IL-23 fails, MRI progression, Not all inflammatory back pain becomes SpA:
Read Article
The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)
Dr. Jack Cush reviews selected news and journal reports from the past week on RheumNow.com.
Read Article
The RheumNow Week in Review – EULAR18 Epilogue (6.22.18)
Dr. Jack Cush reviews EULAR 2018 and the past week's news and reports from RheumNow.com, including DMARDs in OA, the price of Penicillamine, Infections when ANCA+, CV outcomes in gout, NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes.
Read Article
Changing my Mind at EULAR
Each year I attend I hope that I’m going to come across something that changes my practice and this year, I think I may have struck gold at a session on Giant Cell arteritis at EULAR in Amsterdam.
Read Article
